Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

UKMenCar4: A cross-sectional survey of asymptomatic meningococcal carriage amongst UK adolescents at a period of low invasive meningococcal disease incidence.

Bratcher HB, Rodrigues CMC, Finn A, Wootton M, Cameron JC, Smith A, Heath P, Ladhani S, Snape MD, Pollard AJ, Cunningham R, Borrow R, Trotter C, Gray SJ, Maiden MCJ, MacLennan JM.

Wellcome Open Res. 2019 Aug 6;4:118. doi: 10.12688/wellcomeopenres.15362.1. eCollection 2019.

2.

First-in-human randomized study to assess the safety and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine based on ChAd155 viral vector expressing RSV viral proteins F, N and M2-1 in healthy adults.

Cicconi P, Jones C, Sarkar E, Reyes LS, Klenerman P, de Lara C, Hutchings C, Moris P, Janssens M, Fissette LA, Picciolato M, Leach A, Lopez AG, Dieussaert I, Snape MD.

Clin Infect Dis. 2019 Jul 24. pii: ciz653. doi: 10.1093/cid/ciz653. [Epub ahead of print]

PMID:
31340042
3.

Attitudes of Pregnant Women and Healthcare Professionals Toward Clinical Trials and Routine Implementation of Antenatal Vaccination Against Respiratory Syncytial Virus: A Multicenter Questionnaire Study.

Wilcox CR, Calvert A, Metz J, Kilich E, MacLeod R, Beadon K, Heath PT, Khalil A, Finn A, Snape MD, Vandrevala T, Nadarzynski T, Coleman MA, Jones CE.

Pediatr Infect Dis J. 2019 Sep;38(9):944-951. doi: 10.1097/INF.0000000000002384.

PMID:
31261362
4.

Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol.

Ziegler AG, Achenbach P, Berner R, Casteels K, Danne T, Gündert M, Hasford J, Hoffmann VS, Kordonouri O, Lange K, Elding Larsson H, Lundgren M, Snape MD, Szypowska A, Todd JA, Bonifacio E; and the GPPAD Study group.

BMJ Open. 2019 Jun 28;9(6):e028578. doi: 10.1136/bmjopen-2018-028578.

5.

Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials-GPPAD-02 study design and first results.

Winkler C, Haupt F, Heigermoser M, Zapardiel-Gonzalo J, Ohli J, Faure T, Kalideri E, Hommel A, Delivani P, Berner R, Kordonouri O, Roloff F, von dem Berge T, Lange K, Oltarzewski M, Glab R, Szypowska A, Snape MD, Vatish M, Todd JA, Larsson HE, Ramelius A, Kördel JÅ, Casteels K, Paulus J, Ziegler AG, Bonifacio E; GPPAD Study Group.

Pediatr Diabetes. 2019 Sep;20(6):720-727. doi: 10.1111/pedi.12870. Epub 2019 Jun 13.

PMID:
31192505
6.

Common Genetic Variations Associated with the Persistence of Immunity following Childhood Immunization.

O'Connor D, Png E, Khor CC, Snape MD, Hill AVS, van der Klis F, Hoggart C, Levin M, Hibberd ML, Pollard AJ.

Cell Rep. 2019 Jun 11;27(11):3241-3253.e4. doi: 10.1016/j.celrep.2019.05.053.

7.

Persistent circulation of vaccine serotypes and serotype replacement after five years of UK infant immunisation with PCV13.

Kandasamy R, Voysey M, Collins S, Berbers G, Robinson H, Noel I, Hughes H, Ndimah S, Gould K, Fry N, Sheppard C, Ladhani S, Snape MD, Hinds J, Pollard AJ.

J Infect Dis. 2019 Apr 20. pii: jiz178. doi: 10.1093/infdis/jiz178. [Epub ahead of print]

PMID:
31004136
8.

Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study.

Faust SN, Le Roy M, Pancharoen C, Weber MAR, Cathie K, Behre U, Bernatoniene J, Snape MD, Helm K, Medina Pech CE, Henry O, Baccarini C, Povey M, Gillard P.

BMC Pediatr. 2019 Feb 7;19(1):50. doi: 10.1186/s12887-019-1425-7.

9.

Meningococcal meningitis presenting postinfant group B meningococcal immunisation.

So N, Pal R, Snape MD.

Arch Dis Child. 2019 Sep;104(9):924. doi: 10.1136/archdischild-2018-316341. Epub 2018 Dec 5. No abstract available.

PMID:
30518518
10.

Determinants of Influenza and Pertussis Vaccination Uptake in Pregnancy: A Multicenter Questionnaire Study of Pregnant Women and Healthcare Professionals.

Wilcox CR, Calvert A, Metz J, Kilich E, MacLeod R, Beadon K, Heath PT, Khalil A, Finn A, Snape MD, Vandrevala T, Nadarzynski T, Coleman MA, Jones CE.

Pediatr Infect Dis J. 2019 Jun;38(6):625-630. doi: 10.1097/INF.0000000000002242.

PMID:
30418358
11.

Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children.

Claeys C, Chandrasekaran V, García-Sicilia J, Prymula R, Díez-Domingo J, Brzostek J, Marès-Bermúdez J, Martinón-Torres F, Pollard AJ, Růžková R, Carmona Martinez A, Ulied A, Miranda Valdivieso M, Faust SN, Snape MD, Friel D, Ollinger T, Soni J, Schuind A, Li P, Innis BL, Jain VK.

Pediatr Infect Dis J. 2019 Feb;38(2):203-210. doi: 10.1097/INF.0000000000002217.

12.

Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function.

Martinón-Torres F, Bernatowska E, Shcherbina A, Esposito S, Szenborn L, Marti MC, Hughes S, Faust SN, Gonzalez-Granado LI, Yu LM, D'Agostino D, Calabresi M, Toneatto D, Snape MD.

Pediatrics. 2018 Sep;142(3). pii: e20174250. doi: 10.1542/peds.2017-4250. Epub 2018 Aug 1. Erratum in: Pediatrics. 2019 Mar;143(3):.

13.
14.

Differences in Immunization Site Pain in Toddlers Vaccinated With Either the 10- or the 13-Valent Pneumococcal Conjugate Vaccine.

Trück J, Kelly S, Jawad S, Snape MD, Voysey M, Pollard AJ.

Pediatr Infect Dis J. 2018 Apr;37(4):e103-e106. doi: 10.1097/INF.0000000000001894.

PMID:
29329169
15.

Antenatal vaccination against Group B streptococcus: attitudes of pregnant women and healthcare professionals in the UK towards participation in clinical trials and routine implementation.

McQuaid F, Jones C, Stevens Z, Meddaugh G, O'Sullivan C, Donaldson B, Hughes R, Ford C, Finn A, Faust SN, Gbesemete D, Bedford H, Hughes S, Varghese AS, Heath PT, Snape MD.

Acta Obstet Gynecol Scand. 2018 Mar;97(3):330-340. doi: 10.1111/aogs.13288. Epub 2018 Jan 19.

PMID:
29292509
16.

Where next? The emergence of hypervirulent W meningococcus in the Netherlands.

Broad J, Snape MD.

Lancet Public Health. 2017 Oct;2(10):e443-e444. doi: 10.1016/S2468-2667(17)30163-9. Epub 2017 Aug 24. No abstract available.

17.

Respiratory syncytial virus seasonality and its implications on prevention strategies.

Janet S, Broad J, Snape MD.

Hum Vaccin Immunother. 2018 Jan 2;14(1):234-244. doi: 10.1080/21645515.2017.1403707. Epub 2017 Dec 15. Review.

18.

Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.

Goldblatt D, Southern J, Andrews NJ, Burbidge P, Partington J, Roalfe L, Valente Pinto M, Thalasselis V, Plested E, Richardson H, Snape MD, Miller E.

Lancet Infect Dis. 2018 Feb;18(2):171-179. doi: 10.1016/S1473-3099(17)30654-0. Epub 2017 Nov 22.

19.

Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules.

Sadarangani M, Sell T, Iro MA, Snape MD, Voysey M, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, Odueyungbo A, Toneatto D, Pollard AJ; European MenB Vaccine Study Group.

CMAJ. 2017 Oct 16;189(41):E1276-E1285. doi: 10.1503/cmaj.161288.

20.

An increase in accident and emergency presentations for adverse events following immunisation after introduction of the group B meningococcal vaccine: an observational study.

Nainani V, Galal U, Buttery J, Snape MD.

Arch Dis Child. 2017 Aug 9. pii: archdischild-2017-312941. doi: 10.1136/archdischild-2017-312941. [Epub ahead of print]

PMID:
28794096
21.

Emerging clinical experience with vaccines against group B meningococcal disease.

Wilkins AL, Snape MD.

Vaccine. 2018 Aug 28;36(36):5470-5476. doi: 10.1016/j.vaccine.2017.07.056. Epub 2017 Aug 1. Review.

PMID:
28778616
22.

Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402].

Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, Odueyungbo A, Toneatto D, Dull P, Pollard AJ; European Men B Vaccine Study Group.

Vaccine. 2017 May 31;35(24):3279. doi: 10.1016/j.vaccine.2017.04.081. Epub 2017 May 5. No abstract available.

23.

Memory B cell response to a PCV-13 booster in 3.5year old children primed with either PCV-7 or PCV-13.

Trück J, Thompson A, Morales-Aza B, Clutterbuck EA, Voysey M, Clarke E, Snape MD, Kelly DF, Finn A, Pollard AJ.

Vaccine. 2017 May 9;35(20):2701-2708. doi: 10.1016/j.vaccine.2017.03.079. Epub 2017 Apr 6.

PMID:
28392142
24.

Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year.

Winslow RL, Milligan ID, Voysey M, Luhn K, Shukarev G, Douoguih M, Snape MD.

JAMA. 2017 Mar 14;317(10):1075-1077. doi: 10.1001/jama.2016.20644. No abstract available.

PMID:
28291882
25.

Persistence of immune responses induced by Ebola virus vaccines.

Snape MD.

Lancet Glob Health. 2017 Mar;5(3):e238-e239. doi: 10.1016/S2214-109X(17)30039-6. No abstract available.

26.

High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine.

O'Connor D, Clutterbuck EA, Thompson AJ, Snape MD, Ramasamy MN, Kelly DF, Pollard AJ.

Genome Med. 2017 Jan 30;9(1):11. doi: 10.1186/s13073-017-0400-x.

27.

Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.

Pace D, Khatami A, Attard-Montalto S, Voysey M, Finn A, Faust SN, Heath PT, Borrow R, Snape MD, Pollard AJ.

Vaccine. 2016 Dec 7;34(50):6350-6357. doi: 10.1016/j.vaccine.2016.10.038. Epub 2016 Oct 28.

PMID:
28029540
28.

Divergent Memory B Cell Responses in a Mixed Infant Pneumococcal Conjugate Vaccine Schedule.

Trück J, Mitchell R, Jawad S, Clutterbuck EA, Snape MD, Kelly DF, Voysey M, Pollard AJ.

Pediatr Infect Dis J. 2017 May;36(5):e130-e135. doi: 10.1097/INF.0000000000001497.

29.

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.

Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, Odueyungbo A, Toneatto D, Dull P, Pollard AJ; European Men B Vaccine Study Group.

Vaccine. 2017 Jan 5;35(2):395-402. doi: 10.1016/j.vaccine.2016.11.009. Epub 2016 Nov 30. Erratum in: Vaccine. 2017 May 31;35(24):3279.

30.

Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.

Lazarus R, Kelly S, Snape MD, Vandermeulen C, Voysey M, Hoppenbrouwers K, Hens A, Van Damme P, Pepin S, Leroux-Roels I, Leroux-Roels G, Pollard AJ.

PLoS One. 2016 Nov 4;11(11):e0165384. doi: 10.1371/journal.pone.0165384. eCollection 2016.

31.

Attitudes towards antenatal vaccination, Group B streptococcus and participation in clinical trials: Insights from focus groups and interviews of parents and healthcare professionals.

McQuaid F, Pask S, Locock L, Davis E, Stevens Z, Plumb J, Snape MD.

Vaccine. 2016 Jul 25;34(34):4056-61. doi: 10.1016/j.vaccine.2016.06.024. Epub 2016 Jun 16.

PMID:
27318418
32.

Immunisation of the immunocompromised child.

Pinto MV, Bihari S, Snape MD.

J Infect. 2016 Jul 5;72 Suppl:S13-22. doi: 10.1016/j.jinf.2016.04.017. Epub 2016 May 24. Review.

PMID:
27233121
33.

Factors influencing women's attitudes towards antenatal vaccines, group B Streptococcus and clinical trial participation in pregnancy: an online survey.

McQuaid F, Jones C, Stevens Z, Plumb J, Hughes R, Bedford H, Voysey M, Heath PT, Snape MD.

BMJ Open. 2016 Apr 20;6(4):e010790. doi: 10.1136/bmjopen-2015-010790.

34.

Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.

Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, Nuthall E, Voysey M, Silva-Reyes L, McElrath MJ, De Rosa SC, Frahm N, Cohen KW, Shukarev G, Orzabal N, van Duijnhoven W, Truyers C, Bachmayer N, Splinter D, Samy N, Pau MG, Schuitemaker H, Luhn K, Callendret B, Van Hoof J, Douoguih M, Ewer K, Angus B, Pollard AJ, Snape MD.

JAMA. 2016 Apr 19;315(15):1610-23. doi: 10.1001/jama.2016.4218.

PMID:
27092831
35.

The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.

Trück J, Jawad S, Goldblatt D, Roalfe L, Snape MD, Voysey M, Pollard AJ.

Pediatr Infect Dis J. 2016 Jul;35(7):787-93. doi: 10.1097/INF.0000000000001180.

36.

Lymphocyte subpopulations in premature infants: an observational study.

Kent A, Scorrer T, Pollard AJ, Snape MD, Clarke P, Few K, Menson E, Varghese AS, Hughes S, Ladhani SN, Heath PT.

Arch Dis Child Fetal Neonatal Ed. 2016 Nov;101(6):F546-F551. doi: 10.1136/archdischild-2015-309246. Epub 2016 Apr 13.

PMID:
27075591
37.

Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells.

Voysey M, Barker CI, Snape MD, Kelly DF, Trück J, Pollard AJ.

Vaccine. 2016 Mar 29;34(14):1657-64. doi: 10.1016/j.vaccine.2016.02.036. Epub 2016 Feb 23.

PMID:
26920472
38.

Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age.

Snape MD, Voysey M, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Kieninger D, Prymula R, Dull PM, Kohl I, Barone M, Wang H, Toneatto D, Pollard AJ; European MenB Vaccine Study Group.

Pediatr Infect Dis J. 2016 Apr;35(4):e113-23. doi: 10.1097/INF.0000000000001056.

PMID:
26756390
39.

Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study.

Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M; SNIFFLE-2 Study Investigators.

BMJ. 2015 Dec 8;351:h6291. doi: 10.1136/bmj.h6291.

40.

Factors affecting the causality assessment of adverse events following immunisation in paediatric clinical trials: An online survey.

Voysey M, Tavana R, Farooq Y, Heath PT, Bonhoeffer J, Snape MD.

Vaccine. 2015 Dec 16;33(51):7203-7210. doi: 10.1016/j.vaccine.2015.10.126. Epub 2015 Nov 6.

PMID:
26552002
41.

Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination.

Thebault S, Waters P, Snape MD, Cottrell D, Darin N, Hallböök T, Huutoniemi A, Partinen M, Pollard AJ, Vincent A.

PLoS One. 2015 Jun 19;10(6):e0129555. doi: 10.1371/journal.pone.0129555. eCollection 2015.

42.

Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.

Pace D, Khatami A, McKenna J, Campbell D, Attard-Montalto S, Birks J, Voysey M, White C, Finn A, Macloed E, Faust SN, Kent AL, Heath PT, Borrow R, Snape MD, Pollard AJ.

BMJ. 2015 Apr 1;350:h1554. doi: 10.1136/bmj.h1554. Erratum in: BMJ. 2016 May 06;353:i2605.

43.

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.

McQuaid F, Snape MD, John TM, Kelly S, Robinson H, Yu LM, Toneatto D, D'Agostino D, Dull PM, Pollard AJ.

CMAJ. 2015 Apr 21;187(7):E215-E223. doi: 10.1503/cmaj.141200. Epub 2015 Mar 23.

44.

Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy.

Jeppesen CA, Snape MD, Robinson H, Gossger N, John TM, Voysey M, Ladhani S, Okike IO, Oeser C, Kent A, Oliver J, Taylor P, Morales-Aza B, Clarke SC, Casey M, Martins F, Kitchin NR, Anderson AS, Jones H, Jansen KU, Eiden J, Pedneault L, Heath PT, Finn A, Faust SN, Pollard AJ.

J Infect. 2015 Jul;71(1):43-52. doi: 10.1016/j.jinf.2015.02.006. Epub 2015 Feb 21.

45.

Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial.

Hamaluba M, Kandasamy R, Upreti SR, Subedi GR, Shrestha S, Bhattarai S, Gurung M, Pradhan R, Voysey M, Gurung S, Pradhan S, Thapa AK, Maharjan R, Kiran U, Kerridge SA, Hinds J, van der Klis F, Snape MD, Murdoch DR, Kelly S, Kelly DF, Adhikari N, Thorson S, Pollard AJ.

Lancet Infect Dis. 2015 Apr;15(4):405-14. doi: 10.1016/S1473-3099(15)70007-1. Epub 2015 Feb 18.

PMID:
25701560
46.

Safety of live attenuated influenza vaccine in atopic children with egg allergy.

Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M; SNIFFLE Study Investigators.

J Allergy Clin Immunol. 2015 Aug;136(2):376-81. doi: 10.1016/j.jaci.2014.12.1925. Epub 2015 Feb 13.

47.

Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.

Iro MA, Khatami A, Marshall AS, Pace D, Voysey M, McKenna J, Campbell D, Attard-Montalto S, Finn A, White C, Faust SN, Kent A, Heath PT, MacLeod E, Stanford E, Findlow H, Almond R, Bai X, Borrow R, Snape MD, Pollard AJ.

Lancet Infect Dis. 2015 Feb;15(2):172-80. doi: 10.1016/S1473-3099(14)71057-6. Epub 2015 Jan 8.

PMID:
25577661
48.

A cross-sectional observational study of pneumococcal carriage in children, their parents, and older adults following the introduction of the 7-valent pneumococcal conjugate vaccine.

Hamaluba M, Kandasamy R, Ndimah S, Morton R, Caccamo M, Robinson H, Kelly S, Field A, Norman L, Plested E, Thompson BA, Zafar A, Kerridge SA, Lazarus R, John T, Holmes J, Fenlon SN, Gould KA, Waight P, Hinds J, Crook D, Snape MD, Pollard AJ.

Medicine (Baltimore). 2015 Jan;94(1):e335. doi: 10.1097/MD.0000000000000335.

49.

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.

Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJ, Pollard AJ, Turner DP, Bazaz R, Ganguli A, Havelock T, Neal KR, Okike IO, Morales-Aza B, Patel K, Snape MD, Williams J, Gilchrist S, Gray SJ, Maiden MC, Toneatto D, Wang H, McCarthy M, Dull PM, Borrow R.

Lancet. 2014 Dec 13;384(9960):2123-31. doi: 10.1016/S0140-6736(14)60842-4. Epub 2014 Aug 18.

PMID:
25145775
50.

Evaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines--exploratory analyses within a randomised controlled trial.

Khatami A, Clutterbuck EA, Thompson AJ, McKenna JA, Pace D, Birks J, Snape MD, Pollard AJ.

PLoS One. 2014 Jul 14;9(7):e101672. doi: 10.1371/journal.pone.0101672. eCollection 2014.

Supplemental Content

Loading ...
Support Center